ARCT Arcturus Therapeutics Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARCT

Price (delayed)

$26.31

Market cap

$708.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.12

Enterprise value

$387.04M

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
Arcturus Therapeutics Holdings's debt has shrunk by 71% YoY and by 45% QoQ
ARCT's quick ratio is up by 49% year-on-year and by 5% since the previous quarter
The company's EPS has shrunk by 130% QoQ
The net income has dropped by 130% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://arcturusrx.com
Peers: NWBO

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.92M
Market cap
$708.14M
Enterprise value
$387.04M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.52
Price to sales (P/S)
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.32
Earnings
Revenue
$166.8M
EBIT
-$44.48M
EBITDA
-$41.52M
Free cash flow
-$21M
Per share
EPS
-$1.12
Free cash flow per share
-$0.79
Book value per share
$10.42
Revenue per share
$6.26
TBVPS
$16.13
Balance sheet
Total assets
$429.4M
Total liabilities
$150.89M
Debt
$25.91M
Equity
$278.51M
Working capital
$304.6M
Liquidity
Debt to equity
0.09
Current ratio
4.72
Quick ratio
4.62
Net debt/EBITDA
7.73
Margins
EBITDA margin
-24.9%
Gross margin
100%
Net margin
-17.8%
Operating margin
-46.9%
Efficiency
Return on assets
-6.6%
Return on equity
-10.1%
Return on invested capital
-105.7%
Return on capital employed
-12.8%
Return on sales
-26.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-4.81%
1 week
-19.15%
1 month
-20.59%
1 year
-5.63%
YTD
-16.56%
QTD
-22.09%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$166.8M
Gross profit
$166.8M
Operating income
-$78.21M
Net income
-$29.73M
Gross margin
100%
Net margin
-17.8%
Arcturus Therapeutics Holdings's net margin has shrunk by 153% QoQ
The net income has dropped by 130% since the previous quarter
Arcturus Therapeutics Holdings's gross profit has decreased by 44% QoQ and by 19% YoY
The revenue has declined by 44% since the previous quarter and by 19% year-on-year

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
ARCT P/E details
P/E
N/A
P/B
2.52
P/S
4.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.32
The company's EPS has shrunk by 130% QoQ
ARCT's P/B is 37% lower than its 5-year quarterly average of 4.2 but 6% higher than its last 4 quarters average of 2.5
ARCT's equity is up by 3% year-on-year
ARCT's price to sales (P/S) is 90% lower than its 5-year quarterly average of 42.9 but 42% higher than its last 4 quarters average of 3.1
The revenue has declined by 44% since the previous quarter and by 19% year-on-year

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The company's return on sales has shrunk by 186% QoQ
Arcturus Therapeutics Holdings's ROIC has plunged by 147% from the previous quarter
The company's return on equity has shrunk by 130% QoQ
The ROA has shrunk by 130% QoQ

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets is 185% higher than its total liabilities
ARCT's quick ratio is up by 49% year-on-year and by 5% since the previous quarter
ARCT's current ratio is up by 48% YoY and by 5% QoQ
Arcturus Therapeutics Holdings's debt is 91% lower than its equity
The debt to equity has plunged by 74% YoY and by 47% from the previous quarter
Arcturus Therapeutics Holdings's debt has shrunk by 71% YoY and by 45% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.